April 15, 2022
3 min watch
Save
VIDEO: Amyloids in brain may reaccumulate in patients with AD after lecanemab removal
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Patients with Alzheimer’s disease who are treated with lecanemab have shown the potential to reaccumulate brain amyloid after removal of the drug, a speaker said at the 2022 American Academy of Neurology annual meeting.
“Lecanemab produces a very robust time and dose-dependent reduction in brain amyloid, and that’s correlated with the slowing of clinical decline,” Chad Swanson, PhD, executive director of the Neurology Business Group at Eisai Inc., said.
Lecanemab is being developed by Eisai and Biogen for patients with early AD.